Autopsy report · NCT06884683

Nivolumab Plus Metformin in Metastatic Renal Cell Carcinoma

“slow enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years 6 months after it had already started.
• Ran for about 3 years before it stopped.
• 12 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Sponsor type

University, hospital or other

Conditions

Metastatic Renal Cell Carcinoma

Interventions

Metformin

Participants

12

Sites

2

Countries

Italy

Trials that died the same way

• EXCimEr Laser for Long lENgTh Lesions in Below-The-Knee Arteries Study
  “too slow enrollment” (95% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.